$DOO

TD Issues Positive Forecast for BRP (TSE:DOO) Stock Price

TD raised its BRP (TSE:DOO) price target to C$92 from C$84 and kept a “hold” rating, implying 16.66% upside from the stock’s then-current level, BayStreet.CA reported. Other firms cited include RBC (target C$107, “outperform”) and Raymond James (downgraded to “market perform”). BRP last reported Q EPS of C$1.83 on revenue of C$2.39B.

Original reporting
Published May 29, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 7:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TD Issues Positive Forecast for BRP (TSE:DOO) Stock Price — source image
Decision brief

The 30-second read

$DOOBullishLow
01

Why it matters

A higher price objective can attract incremental buyers, but without new company fundamentals (no new guidance/earnings beat in the article), impact is likely confined to sentiment and short-term trading flows.

02

Market read

Traders may use the target raise as a near-term sentiment input, but conviction is reduced by the unchanged Hold stance and lack of new fundamental data.

03

What to watch

The article notes mixed prior analyst actions (downgrades and target cuts), so positioning may already reflect consensus target drift rather than a fresh catalyst.

Relevance 6/10Novelty 4/10Timing: today/next-session sentiment follow-through after the research note

Background

BRP (DOO) recently reported earnings on May 28; this piece focuses on TD’s subsequent price-target adjustment and summarizes other sell-side target/rating changes.

Company-level read

Ticker impact

$DOOBullishMedium confidence
Context

TD raised its BRP price objective to C$92 from C$84 while keeping a Hold rating, implying ~16.7% upside from the stock’s level.

Expected impact

Mild upside bias / mean-reversion support over the next few sessions rather than a breakout move.

Evidence & confidence

The article is a single-broker target change (no new earnings or guidance), and the rating remains Hold, suggesting incremental rather than fundamental repricing.

Market effects

Limited read-across to powersports/vehicle OEM sentiment; this is broker-specific rather than sector-wide guidance.

Primarily affects Canadian-listed BRP sentiment; broader North American powersports complex impact is likely small.

Low global relevance; no supply chain, regulatory, or macro catalyst cited.

Counterpoint

Because TD kept a Hold rating, the market may treat the target raise as incremental and fade the move if broader analyst revisions don’t accelerate.

Key entities

  • BRP

    Powersports manufacturer; subject of the TD price-target raise and the article’s trading/valuation snapshot.

  • TD

    Broker that raised its BRP price objective to C$92 while maintaining a Hold rating.

Related articles

$DOOMed

Wednesday’s analyst upgrades and downgrades

TD Cowen upgraded BRP Inc. (DOO) to 'buy' citing strong demand for side-by-side vehicles and potential tariff exposure reduction. Analyst Brian Morrison raised the target price to $106 and forecasts 6% revenue growth. Air Canada (AC) received a target price increase to $38 from Stifel's Daryl Young following a $2.5B Aeroplan stake sale and strong Q2 results. Scotia's Konark Gupta also raised his target to $37.50. Cadillac Mines (CADY) received an 'outperform' rating from National Bank's Don DeMa

$DOOMed

BRP (TSE:DOO) Stock Price Expected to Rise, Desjardins Analyst Says

Desjardins raised its BRP (TSE:DOO) price target to C$103 from C$97 and kept a “buy” rating, implying 27.95% upside versus the prior close, according to BayStreet.CA. Other analysts adjusted targets: Scotiabank to C$83, National Bank to C$84, BMO to C$120, Canaccord cut to C$90, and Raymond James to “market perform.” BRP shares rose to C$80.50.

$DOOMedAI 9/10

BRP Reports Lower Q1 Profit Over Unfavorable Foreign Exchange Rate, Stock Up

BRP Inc. reported first-quarter profit for the period ended April 30, 2026 fell to C$127.3 million from C$161.0 million in 2025, citing unfavorable FX on U.S.-denominated long-term debt and higher income taxes, partially offset by higher operating income. Revenue rose to C$2,391.8 million. EPS was C$1.73 vs C$2.19. Normalized net income and EPS increased; 2027 guidance: EPS C$3.00–C$3.50, normalized EBITDA C$925–C$975 million, net income C$215–C$250 million. Shares rose on the day.

$PDDMedAI 8/10

Housing, Employment Numbers Featured in Short Week in U.S.

The article previews a short U.S. and Canada market week after Memorial Day, highlighting housing, confidence, jobs, and earnings. It lists U.S. EPS results for PDD, AutoZone, Elbit, Salesforce, Synopsys, Marvell, Costco, Dell, and Autodesk, plus Canada banks’ and other firms’ EPS. Key data include S&P Case-Shiller (March), jobless claims and durable goods (May 23/April), and Canada payroll employment and GDP.

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$BAMedAI 8/10

Boeing’s MAX 10 Schedule Puts 27 United Planes Beyond 2027 as Labor Tensions Rise

Boeing's MAX 10 delays push 27 United Airlines jets to post-2027 delivery, per United's latest filing. Boeing completed flight tests but awaits certification. BA shares fell 7.5% last week, erasing $13.8B in market cap. Labor tensions rise as Boeing engineers reject contract offers, risking a strike. Boeing's Q2 revenue rose 8% to $24.56B, with a $715B backlog. Analysts maintain a positive outlook, with a consensus price target of $274.85.